In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 3, 2014, Pages 697-705

  Chilton, C H ^a   Crowther, G S ^a   Baines, S D ^b   Todhunter, S L ^a   Freeman, J ^c   Locher, H H ^d   Athanasiou, A ^d   Wilcox, M H ^a,c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

^d ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Antimicrobial persistence; Chemostat; MICs

Indexed keywords

CADAZOLID; OXAZOLIDINONE DERIVATIVE;

BACTERIAL LOAD; CLOSTRIDIUM INFECTIONS; DRUG EFFECTS; GASTROINTESTINAL TRACT; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; THEORETICAL MODEL; TREATMENT OUTCOME;

BACTERIAL LOAD; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; GASTROINTESTINAL TRACT; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MODELS, THEORETICAL; OXAZOLIDINONES; TREATMENT OUTCOME;

EID: 84894042563     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt411     Document Type: Article

References (33)

1. George WL, Rolfe RD, Finegold SM. Clostridium difficile and its cytotoxin in feces of patients with antimicrobial agent-associated diarrhea and miscellaneous conditions. J Clin Microbiol 1982; 15: 1049-53.
2. Freeman J, Bauer MP, Baines SD et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23: 529-49.
3. Wiegand PN, Nathwani D, Wilcox MH et al. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 2012; 81: 1-14.
4. Ghantoji SS, Sail K, Lairson DR et al. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 2010; 74: 309-18.
5. Zar FA, Bakkanagari SR, Moorthi KM et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-7.
6. Johnson S.Recurrent Clostridium difficile infection:areviewof risk factors, treatments, and outcomes. J Infect 2009; 58: 403-10.
7. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New Engl J Med 2011; 364: 422-31.
8. Cornely OA, Miller MA, Louie TJ et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 2012; 55 Suppl 2: S154-61.
9. Brazier JS, Fawley W, Freeman J et al.Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 2001; 48: 741-2.
10. Baines SD, O'Connor R, Freeman J et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62: 1046-52.
11. Clostridium difficile Ribotyping Network (CDRN) for England and Northern Ireland. 2010/11 Annual Report. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317133396963 (18 February 2013, date last accessed).
12. Hecht DW, Gerding DN, Osmolski JR et al. In vitro activity of cadazolid against 209 toxigenic isolates of Clostridium difficile. In: Abstracts of the Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 2012. Abstract E-808. American Society for Microbiology,Washington, DC, U.S.A.
13. Locher HH, Pfaff P, Schroeder S et al. Cadazolid, a novel quinolonyl-oxazolidinone antibiotic with potent activity against Clostridium difficile: in vitro antibacterial activity and propensity for resistance development. In: Abstracts of the Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 2012. Abstract C1-1346. American Society for Microbiology, Washington, DC, U.S.A.
14. Louie TBM, Cornely OA, Kracker H et al. Multicentre, double-blind, randomised, phase 2 study evaluating the novel antibiotic, cadazolid, in subjects with Clostridium difficile-associated diarrhoea. In: Abstracts of the Twenty-third European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 2013. Abstract LB-2956. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
15. Rashid MU, Lozano HM, Weintraub A et al. In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden. Anaerobe 2013; 20: 32-5.
16. Freeman J, Wilcox MH. Antibiotic activity against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Chemother 2001; 47: 244-6.
17. Moura I, Spigaglia P, Barbanti F et al. Analysis of metronidazole susceptibility in different Clostridium difficile PCR ribotypes. J Antimicrob Chemother 2013; 68: 362-5.
18. Freeman J, O'Neill FJ, Wilcox MH. Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. J Antimicrob Chemother 2003; 52: 96-102.
19. Baines SD, Freeman J,Wilcox MH. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J Antimicrob Chemother 2005; 55: 974-82.
20. Freeman J, Baines SD, Jabes D et al. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 2005; 56: 717-25.
21. Freeman J, Baines SD, Saxton K et al. Effect of metronidazole on growth and toxin production byepidemic Clostridium difficile PCR ribotypes001 and 027 in a human gut model. J Antimicrob Chemother 2007; 60: 83-91.
22. Baines SD, O'Connor R, Saxton K et al. Comparison of oritavancin versus vancomycin as treatments forclindamycin-induced Clostridium difficile PCR ribotype027infection inahumangut model. J AntimicrobChemother2008; 62: 1078-85.
23. Baines SD, Noel AR, Huscroft GS et al. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model. J Antimicrob Chemother 2011; 66: 1537-46.
24. MacFarlane GT, Macfarlane S, Gibson GR. Validation of a three-stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon. Microb Ecol 1998; 35: 180-7.
25. Brown RB, Martyak SN, Barza M et al. Penetration of clindamycin phosphate into the abnormal human biliary tract. Ann Intern Med 1976; 84: 168-70.
26. Saxton K, Baines SD, Freeman J et al. Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model. Antimicrob Agents Chemother 2009; 53: 412-20.
27. Baines SD, O'Connor R, Saxton K et al. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2009; 63: 520-5.
28. Crowther GS, Baines SD, Todhunter SL et al. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. J Antimicrob Chemother 2013; 68: 168-76.
29. Chilton CH, FreemanJ, Crowther GS et al. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model. J Antimicrob Chemother 2013; 68: 2078-82.
30. Louie TJ, Emery J, Krulicki W et al. OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009; 53: 261-3.
31. Baines SD, Saxton K, Freeman J et al. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2006; 58: 1062-5.
32. Chilton CH, Freeman J, Crowther GS et al. Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model. J Antimicrob Chemother 2012; 67: 951-4.
33. Baines SD, Freeman J, Wilcox MH. Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection. Antimicrob Agents Chemother 2009; 53: 2202-4.